MT 8554

Drug Profile

MT 8554

Alternative Names: MT8554

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurological disorders; Vasomotor symptoms

Most Recent Events

  • 01 Jan 2017 Mitsubishi Tanabe Pharma Corporation completes a phase I trial for Vasomotor symptoms in Germany (unspecified) (NCT02803268)
  • 01 Jun 2016 Phase-I clinical trials in Vasomotor symptoms in Germany (unspecified route) (NCT02803268)
  • 01 Mar 2016 Mitsubishi Tanabe Pharma completes a phase I pharmacokinetics trial in Healthy volunteers in United Kingdom (NCT02675309)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top